NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE
Delisted
NBSE was delisted on the 10th of May, 2024.
21 hedge funds and large institutions have $301K invested in NeuBase Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Holders
21
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$10.7K | |
| 2 | +$3.29K | |
| 3 | +$3 | |
| 4 |
Morgan Stanley
New York
|
+$2 |
Top Sellers
| 1 | -$311K | |
| 2 | -$92.5K | |
| 3 | -$24K | |
| 4 |
CM
CM Management
Gulf Breeze,
Florida
|
-$11K |
| 5 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$6.53K |